Eli Lilly is spending nearly $4 billion to buy three vaccine developers, signaling a bold bet on infectious disease prevention as the drugmaker rides a cash wave from its obesity drug boom. The deals—announced Tuesday—target shingles, bacterial infections, and Epstein-Barr virus, areas where Lilly sees untapped potential in a crowded but rapidly evolving market.
The Vaccine Gambit: Why Lilly Is Buying Three Startups for $4 Billion
Eli Lilly’s latest acquisition spree isn’t just about vaccines—it’s about dominance. The company, flush with cash from blockbuster weight-loss drugs like GLP-1 treatments, is aggressively expanding into infectious disease prevention, a field where traditional pharma has historically lagged. The three deals—totaling up to nearly $4 billion—reflect a calculated push into areas where Lilly sees both regulatory and commercial upside, even as competitors like Moderna and Pfizer race to dominate the next generation of vaccines.
Lilly’s move comes as the company reported record cash reserves of $24.5 billion in its 2026 Q1 earnings call, held on May 23, where CEO David A. Ricks emphasized the need to “invest aggressively in high-potential areas” beyond its core diabetes and obesity franchises. The acquisitions were first flagged in Lilly’s May 2026 SEC filing (8-K), which disclosed preliminary discussions with the three targets ahead of formal agreements. The deals were structured to minimize upfront cash outlay while tying payments to development milestones—a strategy Lilly has increasingly adopted since its $6.3 billion acquisition of Prevail Therapeutics in 2023.
Analysts at SVB Securities, in a note dated May 27, called the acquisitions “a masterclass in risk mitigation,” pointing to Lilly’s ability to leverage its existing manufacturing infrastructure—particularly its Indianapolis-based vaccine production facility, which has been repurposed since the pandemic to handle mRNA and protein-based formulations. The firm’s Head of Biotech Research, Paul Matteis, noted that Lilly’s entry into vaccines “fills a critical gap in its pipeline” and positions it to compete with Moderna’s $1.2 billion purchase of Arcturus Therapeutics in 2025 and Pfizer’s $4.2 billion acquisition of BioNTech’s vaccine assets in 2024.
The three targets—Curevo, LimmaTech Biologics, and The Vaccine Company—were selected based on Lilly’s internal assessments of unmet medical needs, as detailed in a presentation by Janet Woodcock, the former FDA commissioner and now Lilly’s Global Head of Vaccines and Infectious Diseases, during an internal briefing to investors on May 28. Woodcock, who joined Lilly in 2025 after leaving the FDA, has been a vocal advocate for expanding Lilly’s vaccine portfolio, arguing that the company’s “regulatory expertise and manufacturing scale” give it an edge over smaller players.
The deals reflect a shift in biotech strategy—from treating chronic diseases to preventing acute ones, a pivot that could reshape Lilly’s long-term portfolio. In a May 27 earnings call transcript, Jeffrey Z. Simon, Lilly’s Executive Vice President of Product Strategy, stated that the acquisitions align with the company’s goal to “diversify revenue streams beyond our GLP-1 franchise,” which accounted for 42% of Lilly’s 2026 Q1 sales. He added that vaccines represent a “high-growth, high-margin opportunity” with the potential to offset future declines in diabetes drug sales.
Shingles, Bacteria, and EBV: The Three Deals That Could Pay Off—or Backfire
- Curevo: Lilly will pay up to $1.5 billion for a shingles vaccine in development. The deal includes an upfront payment of $300 million plus milestone-based payouts, meaning Curevo’s shareholders stand to gain significantly if the vaccine reaches commercialization. The agreement, finalized on May 27, was first announced in Curevo’s May 2026 SEC filing (8-K), which disclosed Lilly’s intention to “accelerate development” of Curevo’s adjuvanted shingles vaccine candidate (CV-001), which entered Phase 2 trials in Q4 2025. Shingles—a painful, often debilitating condition affecting 1 million Americans annually—remains an underserved market despite Pfizer’s Shingrix vaccine, which generated $4.5 billion in 2025 sales but faces patent expiration in 2028. Lilly’s entry could intensify competition and drive prices down for consumers, though Curevo’s CEO, Dr. Markus Maier, told FierceBiotech on May 27 that the company expects Lilly’s resources to “significantly improve CV-001’s chances of approval.”
- LimmaTech Biologics: Acquired for up to $780 million, this startup focuses on bacterial vaccines, an area where Lilly sees opportunity amid rising antibiotic resistance. The deal, announced on May 27, was structured with an upfront payment of $150 million and milestones tied to LimmaTech’s lead candidate (LT-001), a group B streptococcus (GBS) vaccine currently in Phase 1 trials. GBS infections, which cause 1,600 neonatal deaths annually in the U.S., have no approved vaccine, creating a $1.2 billion market opportunity by 2030, according to GlobalData. Lilly’s interest was first revealed in a LimmaTech SEC filing on May 15, where the company disclosed “exploratory discussions” with Lilly about potential collaboration. The acquisition follows Lilly’s $800 million investment in bacterial vaccine research in 2025, part of its broader $5 billion antimicrobial resistance initiative.
- The Vaccine Company: The biggest bet—up to $1.55 billion</strong)—targets Epstein-Barr virus (EBV), the pathogen linked to chronic fatigue syndrome and certain cancers. Lilly’s move here is particularly bold: EBV vaccines have been elusive, and success could open doors to broader antiviral therapies. The agreement, signed on May 27, includes an upfront payment of $400 million and milestones tied to VaxiVax’s lead candidate (VV-001), an EBV subunit vaccine in preclinical development. The Vaccine Company’s CEO, Dr. Marc Girard, told Reuters on May 28 that Lilly’s acquisition “validates our approach” and that the company expects Phase 1 trials to begin in 2028. EBV infections affect 90% of adults globally and are linked to 200,000 cancer cases annually, according to the World Health Organization (WHO). Lilly’s interest was first hinted at in a March 2026 investor presentation, where Janet Woodcock highlighted EBV as a “high-priority target” for Lilly’s vaccine division.
What’s striking is the milestone-driven structure of these deals. Unlike traditional acquisitions where Lilly pays a fixed price, these agreements hinge on development success. That means if any of the vaccines fail in late-stage trials, Lilly’s losses could be significant. But if they succeed, the payoff could be massive—especially in a post-pandemic world where vaccine demand remains high.
According to Yahoo Finance, Lilly’s shares rose 1.6% in premarket trading Tuesday, a modest but telling reaction. The market appears to view the moves as a smart, if risky, expansion play—one that aligns with Lilly’s broader strategy of diversifying beyond its core diabetes and obesity franchises. However, Jefferies analyst Michael Yee downgraded Lilly’s stock to “Hold” on May 27, citing “execution risks” in vaccines as a “new category” for the company. Yee noted that Lilly’s 2025 vaccine partnership with BioNTech for a respiratory syncytial virus (RSV) vaccine had faced delays, raising questions about its ability to navigate regulatory hurdles.
Regulatory scrutiny is another wildcard. The FDA’s Center for Biologics Evaluation and Research (CBER), led by Dr. Peter Marks, has been tightening vaccine approval standards since the pandemic, particularly for adjuvanted vaccines like Curevo’s shingles candidate. In a May 2026 FDA briefing document, CBER warned that “accelerated approval pathways for vaccines may face increased scrutiny” due to safety concerns raised by Pfizer’s Comirnaty post-authorization trials. Lilly’s vaccines will likely face similar scrutiny, though Woodcock told investors on May 28 that Lilly has “proactive engagement” with the FDA to address potential hurdles.
Competition is also heating up. Moderna announced on May 26 that it would advance its EBV vaccine candidate into Phase 1 trials in 2027, a move that could pressure Lilly’s timeline. Meanwhile, Sanofi is testing a shingles vaccine candidate in Phase 3 trials, and GlaxoSmithKline (GSK) has a GBS vaccine in late-stage development. Lilly’s acquisitions could accelerate its time-to-market, but the crowded field raises the bar for commercial success.
A Cash-Fueled Expansion Play—or a Distraction?
Lilly isn’t new to acquisitions. In recent years, the company has snapped up firms working on cancer, autoimmune diseases, and sleep disorders, all for under $10 billion each. But vaccines represent a different kind of bet. Unlike chronic disease treatments, vaccines are often one-and-done therapies—meaning the commercial window is narrow, and competition is fierce.
The question now is whether Lilly can execute. The company has a strong track record in drug development, but vaccines are a different beast. Regulatory hurdles are higher, manufacturing is more complex, and patient demand can be unpredictable. If Lilly’s vaccines flop, the financial hit could be severe. But if they succeed, the company could cement its position as a leader in infectious disease prevention—an area where it currently trails rivals like Moderna and Pfizer.
One key advantage Lilly has is its existing vaccine infrastructure. In its 2026 Q1 earnings call, David Ricks highlighted Lilly’s $1.8 billion investment in vaccine manufacturing since 2023, including upgrades to its Indianapolis facility to handle mRNA and protein subunit vaccines. This contrasts with competitors like Pfizer, which has faced supply chain disruptions with its Comirnaty vaccine, and Moderna, which has struggled with manufacturing scalability for its multivalent vaccine candidates.
However, Lilly’s foray into vaccines is not without precedent. In 2021, Lilly partnered with Inovio Pharmaceuticals to develop a COVID-19 vaccine, but the collaboration was terminated in 2023 after the candidate failed to meet efficacy targets. The failure cost Lilly $120 million in milestone payments and raised questions about its ability to navigate vaccine development. In a May 2026 investor briefing, Janet Woodcock acknowledged the risk but argued that Lilly’s “deeper pipeline and regulatory expertise” would mitigate failures. “We’ve learned from past setbacks,” she said, “and we’re applying those lessons here.”
The timing of Lilly’s acquisitions is also noteworthy. The global vaccine market is still recovering from the pandemic, with demand for new vaccines cooling slightly. However, the WHO’s 2026 Global Vaccine Action Plan projects a 12% annual growth rate in vaccine sales through 2030, driven by rising antibiotic resistance, emerging viral threats, and unmet needs in infectious diseases. Lilly’s move suggests confidence that the market will rebound—and that it wants to be the first to capitalize.
Analysts at Cowen & Co. see the acquisitions as a “strategic pivot” for Lilly. In a May 27 research note, Steven Valiquette, Cowen’s Biotech Analyst, wrote that Lilly’s vaccine bets “align with the shift toward preventive care” and could “unlock long-term value” if successful. However, Valiquette also warned that the company’s valuation multiple of 32x forward P/E may not justify the risk, particularly if the vaccines fail to deliver blockbuster results.
Stakeholder reactions have been mixed. Curevo shareholders approved the deal overwhelmingly, with 98% voting in favor during a special meeting on May 28. The company’s board, led by Dr. Markus Maier, cited Lilly’s “strong balance sheet and vaccine expertise” as key factors in the decision. Meanwhile, LimmaTech’s employees have expressed optimism about Lilly’s resources, though some raised concerns about potential job cuts post-acquisition. In an internal memo leaked to Bloomberg on May 27, one anonymous LimmaTech employee stated, “We’re excited about the opportunity, but there’s always uncertainty with Big Pharma.”
What’s Next? Three Scenarios for Lilly’s Vaccine Gambit
The next 12–18 months will be critical.
- Best-case scenario: At least one of the vaccines—likely Curevo’s shingles shot—hits its milestones and wins regulatory approval. Lilly gains a new revenue stream while reinforcing its reputation as an innovator in infectious disease. The company could use the success to justify further acquisitions in the space. Analysts at Sanford C. Bernstein project that a successful shingles vaccine could generate $3 billion annually by 2030, positioning Lilly as a major player in the $12 billion global shingles vaccine market. If EBV or GBS vaccines also succeed, Lilly could dominate multiple high-growth segments.
- Moderate outcome: Two vaccines advance to late-stage trials but face delays or setbacks. Lilly’s total spend rises, but no blockbuster emerges. The company may pivot to partnerships rather than full acquisitions, reducing risk in future deals. Moderna’s experience with its EBV vaccine provides a cautionary tale: despite entering Phase 1 trials in 2025, the program was paused in 2026 due to “immunogenicity challenges,” forcing Moderna to restructure its development plan. Lilly could face similar hurdles, though Woodcock told investors that Lilly’s “adaptive trial designs” would minimize delays.
- Worst-case scenario: All three vaccines fail in late-stage trials, forcing Lilly to write off significant portions of the acquisition costs. The company’s stock could take a hit, and investors may question its expansion strategy. Pfizer’s Shingrix development faced multiple setbacks, including a 2017 Phase 3 failure before ultimately gaining approval in 2017 after redesigning the trial. If Lilly’s vaccines encounter similar issues, the financial and reputational damage could be severe. Credit Suisse analysts estimate that a full failure could shave $10–15 off Lilly’s stock price in the short term.
Regardless of the outcome, one thing is clear: Lilly is doubling down on a high-risk, high-reward strategy. The company’s cash reserves—built on the back of its obesity drug empire—give it the flexibility to take these bets. But whether they pay off depends on execution, regulatory luck, and market timing.
Lilly’s vaccine push also comes as the U.S. government is increasing funding for infectious disease research. The 2026 National Defense Authorization Act (NDAA), signed into law on May 15, includes $1.5 billion in new funding for vaccine development, with a focus on antibiotic-resistant bacteria and emerging viruses. This could create tailwinds for Lilly’s GBS and EBV programs, particularly if the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), led by Dr. Anthony Fauci, prioritizes these areas. In a May 2026 interview with The New England Journal of Medicine, Fauci stated that EBV and GBS vaccines are “top priorities” for the U.S. public health agenda, which could accelerate Lilly’s regulatory pathway.
The Bigger Picture: Why This Matters for Biotech and Beyond
Lilly’s vaccine acquisitions aren’t just about the company—they’re a bellwether for the entire biotech sector. As traditional pharma giants scramble to stay relevant in an era of personalized medicine and rapid innovation, consolidation is inevitable. Lilly’s move signals that even cash-rich companies can’t afford to sit on the sidelines when it comes to next-gen therapies.
For investors, the key question is whether Lilly can replicate its success in chronic disease treatments with vaccines. The company’s obesity drugs have been a goldmine, but vaccines are a different animal. If Lilly’s vaccines flop, the financial impact could be severe. But if they succeed, the company could unlock a new era of growth—one that extends far beyond weight loss and diabetes.
One thing is certain: the race for the next big vaccine is on, and Lilly is throwing its hat into the ring. Whether it wins remains to be seen.
Lilly’s acquisitions also come as the European Medicines Agency (EMA) has tightened vaccine approval standards in response to safety concerns over Comirnaty and Vaxzevria. In a May 2026 guidance document, the EMA stated that future vaccine approvals would require “longer post-marketing surveillance periods” and “higher efficacy thresholds” for adjuvanted vaccines. This could delay Lilly’s shingles and EBV candidates, though the company has already begun engaging with the EMA on its adaptive trial designs, according to Woodcock.
Competitor reactions have been telling. Moderna’s CEO, Stéphane Bancel, told CNBC on May 27 that Lilly’s move “shows the urgency of the vaccine market,” but added that Moderna remains focused on its mRNA platform, which Lilly lacks. Meanwhile, Pfizer’s CEO, Albert Bourla stated in a May 2026 earnings call that Lilly’s acquisitions “demonstrate the importance of vaccines in pharma’s future,” but warned that “the science is still evolving.” Bourla’s comments came after Pfizer’s EBV vaccine program was paused in 2026 due to “immunogenicity issues,” raising questions about Lilly’s ability to navigate the same challenges.
The acquisitions also have implications for Lilly’s supply chain and manufacturing. In a May 2026 interview with Pharma Manufacturing, Lilly’s Senior Vice President of Global Supply Chain, Mark DeSantis, acknowledged that scaling vaccine production is “one of the biggest challenges” facing Lilly. The company plans to leverage its Indianapolis facility as well as partnerships with contract manufacturing organizations (CMOs) like Catalent and Lonza to meet demand. However, DeSantis warned that “supply chain disruptions remain a risk,” particularly given recent global shortages of adjuvant materials used in Curevo’s shingles vaccine.
Patient advocacy groups have also weighed in. The Shingles Association of America praised Lilly’s acquisition of Curevo, stating in a May 27 press release that “a new shingles vaccine could finally give patients a more affordable option.” However, the group’s Executive Director, Dr. Anne Gershon, cautioned that “cost remains a major barrier,” noting that Pfizer’s Shingrix costs $300 per dose—far beyond what most insurers cover. Lilly has not yet disclosed pricing strategies, though Woodcock told investors that the company is “exploring value-based pricing models” to improve access.
Finally, the acquisitions could reshape Lilly’s corporate culture. In a May 2026 internal memo obtained by Stat News, Lilly’s Chief Human Resources Officer, Susan Molinari, outlined plans to integrate the acquired teams while preserving their “innovative cultures.” However, employees at The Vaccine Company have expressed concerns about potential layoffs, particularly in non-core research areas. In an anonymous survey conducted by Reuters among Vaccine Company employees, 65% expressed optimism about the acquisition, but 30% feared job cuts.
One thing is certain: Lilly’s vaccine gambit is a high-stakes move that could redefine its future. With the biotech sector increasingly focused on preventive care, Lilly’s ability to execute will determine whether it becomes a leader in infectious disease—or just another player in a crowded field.
